This document provides an agenda and summaries for Sanofi's Q4 2023 results presentation. The agenda includes sections on R&D update, Biopharma update, Consumer Healthcare update, Growth engine outlook for 2024, and Financial performance. Some key highlights include: - Specialty Care and Vaccines drove strong growth, with Dupixent sales adding €2.8 billion. - 2023 launches exceeded sales expectations, bringing in over €2.2 billion combined. - The pipeline has numerous expected milestones in 2024, including Dupixent COPD approval and results from multiple Phase 2 and 3 trials. - An acquisition of INBRX-101 was announced to add an innovative asset for